Scott Gottlieb can start work now reshaping the FDA to meet lawmakers’ expectations for an agency that can speed up new drug approvals even more, without sacrificing the gold standard on safety and efficacy data that protect patients’ health.
Health and Human Services Secretary Tom Price swore Gottlieb in on Thursday morning, making him the nation’s 23rd Commissioner of Food and Drugs.
A physician, cancer survivor, FDA veteran and biopharma investor and consultant, Gottlieb was hammered by Democrats for his close business ties in the industry, which Republicans celebrated as a sign of experience and expertise. A clear favorite in biopharma circles among all the names in circulation for the job, Gottlieb will have broad power to set speed and safety limits for the agency and drug developers.
Everyone in this business will be watching every step.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription